GlobeNewsWire
20 Oct 2026, 23:30 UTC · 1h ago
Impact · against what's priced in
Ascentage Pharma receives a modest catalyst as lisaftoclax gains Breakthrough Therapy Designation in China for treatment-naïve CLL/SLL. This regulatory milestone potentially accelerates the commercial timeline and revenue realization, shifting the growth trajectory forward.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Ascentage Pharma's lisaftoclax (APG-2575) received Breakthrough Therapy Designation (BTD) from China's NMPA for treatment-naïve CLL/SLL patients.
Newannounced today, Oct 20, 2026
So whatBTD typically accelerates the review timeline, potentially pulling forward the commercial launch and revenue recognition into FY2027.
More positive than 94% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The BTD for lisaftoclax in treatment-naïve CLL/SLL patients likely accelerates the NMPA review process, potentially pulling forward commercial launch and revenue recognition into FY2027.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 91% of ticker scores this week
The company's drug lisaftoclax received Breakthrough Therapy Designation from China's NMPA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
1h ago
—
AAPG hasn't traded since this ran. Last close $15.92 (Oct 20); the reaction starts at the next open.
AAPG chart →
